Safety and side-effects of buprenorphine in the clinical management of heroin addiction
References (40)
Buprenorphine as new treatment for heroin dependence
Drug and Alcohol Depend.
(1985)Buprenorphine
Drug and Alcohol Depend
(1985)- et al.
Effects of buprenorphine in heroin addicts
Drug and Alcohol Depend.
(1987) - et al.
Buprenorphine detoxification from opioid dependence: a pilot study
Life Sci.
(1988) - et al.
Cocaine-induced hepatotoxicity in humans
Am. J. Gastroenterol.
(1987) Acute hepatic insufficiency of the chronic alcoholic — revisited
Am. J. Med.
(1983)- et al.
The animal pharmacology of buprenorphine, an oripavine analgesic agent
Br. J. Pharmacol.
(1977) - et al.
The effects of morphineand nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog
J. Pharmacol. Exp. Ther.
(1976) - et al.
Human pharmacology and abuse potential of the analgesic buprenorphine
Arch. Gen. Psychiatry
(1978) Clinical pharmacology and toxicology of analgesic drugs: buprenorphine — recent information
Sublingual versus subcutaneous buprenorphine in opiate abusers
Clin. Pharmacol. Ther.
Buprenorphine: a new maintenance opiate?
Med. J. Aust.
A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts
Clin. Pharmacol. Ther.
Comparative study on the circulatory and respiratory effects of buprenorphine and methadone
Acta. Anesth. Belg.
Buprenorphine: dose related blockade of opioid challenge effects in opioid dependent humans
J. Pharmacol. Exp. Ther.
Use of buprenorphine in the treatment of opiate addiction. I: Physiologic and behavioral effects during a rapid dose induction
Clin. Pharmacol. Ther.
Use of buprenorhpine in the treatment of opiate addiction. II: Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal
Clin. Pharmacol. Ther.
Adverse drug reactions, A critical review
J. Am. Med. Assoc.
Buprenorphine effects on human heroin self-administration: an operant analysis
J. Pharmacol. Exp. Ther.
Principles and Procedures of Statistics. A Biometrical Approach
Cited by (90)
“You get that craving and you go for a half-hour run”: Exploring the acceptability of exercise as an adjunct treatment for substance use disorder
2021, Mental Health and Physical ActivityCitation Excerpt :All four of these approaches have shown to be beneficial in the treatment of SUD (Farrell et al., 1994; Mattick, Breen, Kimber, & Davoli, 2014; Skinner, Lahmek, Pham, & Aubin, 2014; Srisurapanount & Jarusuraisin, 2005). However, side effects are associated with all pharmacological approaches for SUD (Kreek, 1973; Lange, Fudala, Dax, & Johnson, 1990; Malcolm, Olive, & Lechner, 2008; Srisurapanount & Jarusuraisin, 2005). Finally, in terms of the patient's perspective on integrating pharmacotherapy for AUD, there were concerns over the safety of the treatment, not wanting to substitute one substance for another, and believing their condition does not warrant pharmacological aid (Haley, Pinsker, Gerould, Wisdom, & Hagedorn, 2019).
Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment
2018, Drug and Alcohol DependenceCitation Excerpt :Factor 2 (“Overmedication”) explains 24.9% of the variance and the ODAS items that load onto this factor are precisely those that measure this phenomenon. If symptoms of opioid blockade, OWS, and craving (items 2–5) can be considered “classic” indicators of dose adequacy (Amass et al., 1994; Bickel et al., 1988; Fudala et al., 1990, 2003; Ling et al., 1998, 2005; Walsh et al., 1995) and the continued use of heroin (item 1) can be considered an indicator of dose inadequacy (Hillhouse et al., 2011; Northrup et al., 2015; Heikman et al., 2017), then we can consider avoidance of overmedication (item 6) as an indicator of “good practices” (Lange et al., 1990). In our study, 17.8% of patients with buprenorphine doses classified as “inadequate” had significant symptoms of overmedication.
Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
2016, Journal of Substance Abuse TreatmentNaltrexone-facilitated buprenorphine discontinuation: A feasibility trial
2015, Journal of Substance Abuse TreatmentCitation Excerpt :Maintenance treatment with buprenorphine (often in combination with naloxone, as Suboxone®, to preclude inappropriate use) is an effective and increasingly popular approach to opioid dependence, with retention rates found to be as high as 50% at 6 months (Mattick, Kimber, Breen, & Davoli, 2008). Buprenorphine is a partial μ-opioid agonist and k-antagonist that works to ameliorate withdrawal phenomena and opioid craving, as well as attenuate the effects of co-administered opioids (Comer, Walker, & Collins, 2005; Lange, Fudala, Dax, et al., 1990; Orman & Keating, 2009). As with methadone, however, there is limited information about when or how buprenorphine can be safely discontinued once individuals achieve sustained full remission.
Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient
2014, Best Practice and Research: Clinical Anaesthesiology